Scarica l'app Stockscreener
456.35
1.01%
-4.64
Dopo l'orario di chiusura:
456.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$460.99
Aprire:
$465.005
Volume 24 ore:
969.07K
Relative Volume:
0.86
Capitalizzazione di mercato:
$59.82B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-184.99
EPS:
-2.4669
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+2.23%
1M Prestazione:
+1.99%
6M Prestazione:
+74.07%
1 anno Prestazione:
+69.31%
Intervallo 1D:
$448.47
$465.00
Intervallo di 1 settimana:
$445.22
$467.42
Portata 52W:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After ZENITH Phase 3 Trial Launch and HELIOS-B Data Reveal - simplywall.st
Alnylam Pharma Secures $500M Credit Agreement - TipRanks
Alnylam Pharmaceuticals says on Sept 30, entered into credit agreement with Bank of AmericaSEC filing - MarketScreener
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price actionGap Down & Fast Moving Stock Watchlists - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickJuly 2025 Retail & Weekly Momentum Picks - newser.com
Does Alnylam Pharmaceuticals Inc. show high probability of rebound2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendQuarterly Trade Review & Stock Market Timing Techniques - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutShare Buyback & Community Consensus Trade Alerts - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.2025 Key Highlights & AI Enhanced Trading Signals - newser.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam (ALNY) Reports 238% Growth in Amvuttra Since February Launch, RBC Raises Price Target - Yahoo Finance
Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots - Bloomberg.com
Alnylam Pharmaceuticals (ALNY) Pulls Ad After FDA Warning - GuruFocus
Alnylam yanks Amvuttra TV ad following FDA letterreport - Seeking Alpha
Cambridge-based Alnylam Pharmaceuticals pulls TV ad after Trump crackdown on drug industry spots - The Boston Globe
Alnylam pulls heart drug TV ad amid FDA crackdown - Investing.com
Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5% - MSN
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Alnylam (ALNY) Begins Phase 3 Trial for Hypertension Drug Zilebe - GuruFocus
Alnylam doses first patient in phase 3 trial of zilebesiran for heart outcomes - MarketScreener
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
U.S. Porphyria Treatment Market Set to Witness Massive Growth - openPR.com
Alnylam Pharmaceuticals Inc Stock Analysis and ForecastStock Buyback Announcements & Individual Stock Tracking Service - earlytimes.in
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growth2025 Breakouts & Breakdowns & AI Forecast for Swing Trade Picks - newser.com
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - Insider Monkey
$15B+ Deal Veteran Eric Olson Joins Rare Disease Leader Ultragenyx as Chief Business Officer - Stock Titan
Alnylam Joins Genomic Alliance To Boost RNAi Drug Discovery - Technology Networks
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance - Yahoo Finance
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com
Wealth Enhancement Advisory Services LLC Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way? - Yahoo Finance
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratios2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
What analysts say about Alnylam Pharmaceuticals Inc stockSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with Strong Buy Ratings and Strategic Collaborations - DirectorsTalk Interviews
Vutrisiran treatment reduces GI events in ATTR-CM patients by up to 49% - Investing.com Nigeria
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):